



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

March 2016





© 2016 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

**BC Centre for Excellence in HIV/AIDS
Drug Treatment Program**

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

March 2016

N = 7006



Health Authority	Male	Female	All
FRASER	1315	386	1701
INTERIOR	361	96	457
NORTHERN	128	78	206
VANCOUVER COASTAL	3336	460	3796
VANCOUVER ISLAND	655	152	807
	5795	1172	6967
		Unknown/not stated:	39
		Total:	7006

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (March 2011 - March 2016)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (March 2011 - March 2016)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (March 2011 - March 2016)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (March 2011 - March 2016)






1.6 Percent Distribution of Active Participants by CD4 Count (March 2011 - March 2016)






1.7 Percent Distribution of Inactive Participants by CD4 Count (March 2011 - March 2016)






1.8 Active and Inactive Participants (March 2011 - March 2016)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (March 2011 - March 2016)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (March 2011 - March 2016)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(March 2011 - March 2016)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (March 2011 - March 2016)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(March 2011 - March 2016)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (March 2011 - March 2016)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(March 2011 - March 2016)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (March 2011 - March 2016)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(March 2011 - March 2016)






1.18 Baseline CD4 for Antiretroviral First Starts (March 2011 - March 2016)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(March 2011 - March 2016)**






1.20 Cumulative Resistance Testing Results by Resistance Category (March 2011 - March 2016)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (March 2011 - March 2016)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2016
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	24	5	0	5	5	810	5	<40	4
1988	24	7	0	7	7	530	7	<40	3
1989	23	57	2	59	52	520	58	<40	3
1990	22	61	1	62	56	530	60	<40	3
1991	22	37	3	40	34	555	39	<40	3
1992	22	68	7	75	60	575	75	<40	3
1993	21	147	14	161	143	540	155	<40	3
1994	19	95	14	109	88	585	105	<40	3
1995	19	126	24	150	115	550	142	<40	3
1996	17	370	61	431	373	600	417	<40	3
1997	15	303	40	343	298	615	330	<40	3
1998	15	215	47	262	216	590	250	<40	3
1999	14	185	42	227	188	540	214	<40	3
2000	15	140	38	178	152	560	171	<40	3
2001	14	131	35	166	137	580	159	<40	3
2002	13	140	32	172	139	590	166	<40	3
2003	12	171	35	206	174	595	196	<40	3
2004	11	182	46	228	197	571	215	<40	3
2005	11	209	49	258	214	580	244	<40	3
2006	10	210	47	257	202	570	240	<40	3
2007	9	281	55	336	288	590	325	<40	3
2008	8	312	72	384	312	625	354	<40	3
2009	7	346	80	426	354	650	408	<40	3
2010	6	312	73	385	323	630	365	<40	3
2011	5	367	82	449	378	652	428	<40	3
2012	4	301	67	368	310	685	352	<40	3
2013	3	302	73	375	305	629	359	<40	3
2014	2	317	60	377	306	680	366	<40	3
2015	1	356	59	415	354	580	401	<40	3
2016	0	61	20	81	76	450	77	224	3
Total:		5814	1178	6992					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2015	6742	760	2430	<40	2114	580
FEB-2015	6792	753	1978	<40	1731	570
MAR-2015	6837	747	2173	<40	1897	570
APR-2015	6849	739	2149	<40	1908	580
MAY-2015	6888	739	2032	<40	1788	560
JUN-2015	6902	740	2254	<40	1962	580
JUL-2015	6927	739	2038	<40	1798	580
AUG-2015	6924	752	2075	<40	1774	580
SEP-2015	6924	749	2265	<40	1970	580
OCT-2015	6959	739	2101	<40	1801	590
NOV-2015	7016	721	2065	<40	1799	580
DEC-2015	6996	724	2016	<40	1757	600
JAN-2016	6984	735	2265	<40	1908	590
FEB-2016	6998	736	2066	<40	1735	590
MAR-2016	7006	738	2155	<40	1790	600

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2015	1511	2045	105	1364	86	315
FEB-2015	1493	2120	101	78	86	380
MAR-2015	1467	2292	101	56	92	405
APR-2015	1473	2263	83	2239	68	465
MAY-2015	1456	2372	73	148	60	430
JUN-2015	1474	2295	96	106	89	430
JUL-2015	1468	2344	71	938	55	379
AUG-2015	1479	2304	82	2341	73	440
SEP-2015	1504	2232	91	128	79	349
OCT-2015	1485	2356	80	<40	65	410
NOV-2015	1456	2497	84	223	71	430
DEC-2015	1494	2324	78	384	61	330
JAN-2016	1504	2339	113	<40	87	470
FEB-2016	1501	2370	79	353	63	330
MAR-2016	1507	2342	85	130	79	440

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2015	6709	1511	13	24	149	187	-34	11955
FEB-2015	6761	1493	7	36	188	162	52	12007
MAR-2015	6812	1467	7	29	174	143	51	12047
APR-2015	6811	1473	15	28	168	172	-1	12083
MAY-2015	6851	1456	9	33	171	149	40	12124
JUN-2015	6873	1474	5	36	153	160	22	12171
JUL-2015	6908	1468	5	25	166	149	35	12209
AUG-2015	6905	1479	7	19	145	157	-3	12239
SEP-2015	6901	1504	9	32	157	181	-4	12280
OCT-2015	6930	1485	14	25	171	147	29	12317
NOV-2015	6987	1456	9	29	186	147	57	12358
DEC-2015	6966	1494	11	22	151	181	-21	12391
JAN-2016	6959	1504	9	16	153	165	-7	12412
FEB-2016	6977	1501	5	18	174	164	18	12440
MAR-2016	6992	1507	6	25	168	170	15	12474

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2015	48	6180	440	74	6742	0.71%	91.66%	6.53%	1.10%	100.00%
FEB-2015	49	6219	451	73	6792	0.72%	91.56%	6.64%	1.07%	100.00%
MAR-2015	47	6287	436	67	6837	0.69%	91.96%	6.38%	0.98%	100.00%
APR-2015	46	6301	435	67	6849	0.67%	92.00%	6.35%	0.98%	100.00%
MAY-2015	47	6342	431	68	6888	0.68%	92.07%	6.26%	0.99%	100.00%
JUN-2015	49	6335	446	72	6902	0.71%	91.78%	6.46%	1.04%	100.00%
JUL-2015	46	6361	453	67	6927	0.66%	91.83%	6.54%	0.97%	100.00%
AUG-2015	48	6362	444	70	6924	0.69%	91.88%	6.41%	1.01%	100.00%
SEP-2015	48	6373	439	64	6924	0.69%	92.04%	6.34%	0.92%	100.00%
OCT-2015	51	6402	442	64	6959	0.73%	92.00%	6.35%	0.92%	100.00%
NOV-2015	54	6450	445	67	7016	0.77%	91.93%	6.34%	0.95%	100.00%
DEC-2015	52	6433	449	62	6996	0.74%	91.95%	6.42%	0.89%	100.00%
JAN-2016	53	6420	450	61	6984	0.76%	91.92%	6.44%	0.87%	100.00%
FEB-2016	52	6448	439	59	6998	0.74%	92.14%	6.27%	0.84%	100.00%
MAR-2016	53	6454	438	61	7006	0.76%	92.12%	6.25%	0.87%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	Lamivudine		Abacavir		Zidovudine		Stavudine		Didanosine		Emtricitabine		Tenofovir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	10 29%	2584 40%	10 29%	2221 34%	0 0%	127 2%	0 0%	19 0%	0 0%	11 0%	25 71%	3847 59%	25 71%	4211 64%
FEB-2015	8 15%	2593 39%	8 15%	2228 34%	0 0%	127 2%	0 0%	19 0%	0 0%	9 0%	44 85%	3883 59%	44 85%	4246 64%
MAR-2015	10 25%	2610 39%	10 25%	2253 34%	0 0%	124 2%	0 0%	18 0%	0 0%	10 0%	30 75%	3916 59%	30 75%	4272 64%
APR-2015	10 29%	2626 40%	10 29%	2267 34%	0 0%	117 2%	0 0%	16 0%	0 0%	9 0%	24 69%	3916 59%	24 69%	4272 64%
MAY-2015	8 20%	2640 40%	7 18%	2282 34%	0 0%	118 2%	0 0%	14 0%	0 0%	9 0%	32 80%	3929 59%	33 83%	4283 64%
JUN-2015	10 21%	2635 39%	10 21%	2289 34%	0 0%	115 2%	0 0%	15 0%	0 0%	9 0%	37 79%	3946 59%	37 79%	4297 64%
JUL-2015	4 11%	2659 40%	4 11%	2313 34%	0 0%	111 2%	0 0%	14 0%	0 0%	9 0%	34 89%	3947 59%	34 89%	4297 64%
AUG-2015	12 40%	2675 40%	11 37%	2334 35%	1 3%	111 2%	0 0%	12 0%	0 0%	9 0%	18 60%	3943 59%	18 60%	4283 64%
SEP-2015	17 41%	2715 40%	15 37%	2373 35%	0 0%	107 2%	1 2%	13 0%	0 0%	6 0%	24 59%	3912 58%	24 59%	4252 63%
OCT-2015	11 30%	2747 41%	10 27%	2404 36%	0 0%	102 2%	0 0%	13 0%	0 0%	8 0%	26 70%	3903 58%	27 73%	4241 63%
NOV-2015	17 41%	2790 41%	15 37%	2445 36%	1 2%	102 2%	0 0%	13 0%	0 0%	8 0%	24 59%	3915 58%	25 61%	4247 63%
DEC-2015	5 15%	2797 41%	5 15%	2458 36%	0 0%	95 1%	0 0%	12 0%	0 0%	8 0%	28 85%	3890 57%	28 85%	4215 62%
JAN-2016	4 19%	2825 42%	4 19%	2492 37%	0 0%	93 1%	0 0%	11 0%	0 0%	8 0%	17 81%	3860 57%	17 81%	4178 62%
FEB-2016	10 36%	2856 42%	9 32%	2524 37%	1 4%	94 1%	0 0%	11 0%	0 0%	8 0%	18 64%	3836 57%	18 64%	4143 61%
MAR-2016	9 26%	2879 42%	7 21%	2544 38%	1 3%	94 1%	0 0%	11 0%	0 0%	8 0%	25 74%	3819 56%	26 76%	4122 61%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		Atazanavir		Darunavir		Lopinavir		Nelfinavir		Ritonavir		Saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	0 0%	12 0%	6 50%	2030 60%	6 50%	931 28%	0 0%	383 11%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
FEB-2015	0 0%	10 0%	8 31%	2030 60%	18 69%	960 28%	0 0%	380 11%	0 0%	5 0%	0 0%	1 0%	0 0%	17 1%
MAR-2015	0 0%	11 0%	8 47%	2044 60%	8 47%	971 29%	0 0%	375 11%	1 6%	6 0%	0 0%	1 0%	0 0%	17 0%
APR-2015	0 0%	12 0%	7 33%	2025 60%	14 67%	990 29%	0 0%	364 11%	0 0%	6 0%	0 0%	1 0%	0 0%	18 1%
MAY-2015	0 0%	12 0%	10 63%	2001 59%	6 38%	1020 30%	0 0%	360 11%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
JUN-2015	0 0%	11 0%	8 44%	1967 58%	10 56%	1037 31%	0 0%	359 11%	0 0%	5 0%	0 0%	1 0%	0 0%	18 1%
JUL-2015	0 0%	10 0%	1 7%	1959 58%	11 79%	1050 31%	1 7%	352 10%	0 0%	5 0%	0 0%	1 0%	1 7%	19 1%
AUG-2015	0 0%	11 0%	1 9%	1947 58%	7 64%	1054 31%	3 27%	346 10%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
SEP-2015	0 0%	11 0%	4 25%	1913 58%	11 69%	1061 32%	1 6%	338 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
OCT-2015	0 0%	10 0%	5 31%	1900 57%	10 63%	1088 33%	1 6%	331 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%
NOV-2015	0 0%	10 0%	5 31%	1878 56%	9 56%	1108 33%	2 13%	329 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%
DEC-2015	0 0%	11 0%	3 25%	1840 56%	8 67%	1119 34%	1 8%	328 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%
JAN-2016	0 0%	11 0%	5 45%	1827 55%	5 45%	1131 34%	1 9%	327 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
FEB-2016	0 0%	10 0%	6 46%	1797 55%	6 46%	1161 35%	1 8%	318 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
MAR-2016	0 0%	9 0%	4 25%	1772 55%	11 69%	1176 36%	1 6%	299 9%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	Tipranavir			
	Initial		All	
JAN-2015	0	0%	1	0%
FEB-2015	0	0%	1	0%
MAR-2015	0	0%	1	0%
APR-2015	0	0%	1	0%
MAY-2015	0	0%	1	0%
JUN-2015	0	0%	1	0%
JUL-2015	0	0%	1	0%
AUG-2015	0	0%	1	0%
SEP-2015	0	0%	1	0%
OCT-2015	0	0%	1	0%
NOV-2015	0	0%	1	0%
DEC-2015	0	0%	1	0%
JAN-2016	0	0%	1	0%
FEB-2016	0	0%	1	0%
MAR-2016	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	Efavirenz		Etravirine		Nevirapine		Ralpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	6 75%	1174 45%	0 0%	306 12%	0 0%	900 34%	2 25%	253 10%
FEB-2015	4 50%	1169 45%	0 0%	306 12%	0 0%	892 34%	4 50%	250 10%
MAR-2015	7 88%	1167 45%	0 0%	303 12%	0 0%	889 34%	1 13%	255 10%
APR-2015	4 67%	1148 44%	1 17%	305 12%	0 0%	888 34%	1 17%	259 10%
MAY-2015	7 58%	1139 44%	1 8%	309 12%	0 0%	887 34%	4 33%	260 10%
JUN-2015	2 29%	1133 44%	0 0%	317 12%	0 0%	877 34%	5 71%	262 10%
JUL-2015	8 89%	1122 44%	0 0%	311 12%	0 0%	880 34%	1 11%	260 10%
AUG-2015	4 80%	1104 43%	0 0%	307 12%	0 0%	879 35%	1 20%	253 10%
SEP-2015	8 89%	1097 43%	1 11%	305 12%	0 0%	873 35%	0 0%	256 10%
OCT-2015	2 50%	1084 43%	0 0%	312 12%	1 25%	867 35%	1 25%	251 10%
NOV-2015	4 67%	1076 43%	0 0%	312 12%	0 0%	865 35%	2 33%	254 10%
DEC-2015	3 100%	1059 43%	0 0%	312 13%	0 0%	863 35%	0 0%	254 10%
JAN-2016	2 100%	1037 42%	0 0%	302 12%	0 0%	855 35%	0 0%	256 10%
FEB-2016	3 60%	1009 42%	0 0%	306 13%	1 20%	857 35%	1 20%	260 11%
MAR-2016	2 50%	998 41%	0 0%	307 13%	1 25%	854 35%	1 25%	260 11%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	Dolutegravir		Elvitegravir		Maraviroc		Raltegravir		Enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	13 72%	541 30%	4 22%	349 19%	1 6%	68 4%	1 6%	879 49%	0 0%	1 0%
FEB-2015	14 58%	577 31%	8 33%	355 19%	0 0%	74 4%	2 8%	880 48%	0 0%	1 0%
MAR-2015	9 50%	600 32%	5 28%	367 20%	0 0%	69 4%	4 22%	869 47%	0 0%	2 0%
APR-2015	7 50%	628 33%	4 29%	373 20%	2 14%	67 4%	1 7%	862 45%	0 0%	2 0%
MAY-2015	11 65%	665 34%	4 24%	382 20%	1 6%	70 4%	2 12%	864 44%	0 0%	2 0%
JUN-2015	15 56%	710 35%	8 30%	396 20%	0 0%	72 4%	4 15%	875 43%	0 0%	1 0%
JUL-2015	11 58%	746 36%	4 21%	404 20%	0 0%	71 3%	4 21%	866 42%	0 0%	1 0%
AUG-2015	11 69%	782 38%	4 25%	413 20%	0 0%	70 3%	1 6%	854 41%	0 0%	1 0%
SEP-2015	17 85%	849 40%	1 5%	412 19%	0 0%	65 3%	2 10%	855 40%	0 0%	1 0%
OCT-2015	14 70%	890 40%	6 30%	435 20%	0 0%	65 3%	0 0%	851 39%	0 0%	1 0%
NOV-2015	15 71%	940 42%	6 29%	439 19%	0 0%	67 3%	0 0%	854 38%	0 0%	1 0%
DEC-2015	11 50%	990 43%	10 45%	446 19%	0 0%	66 3%	1 5%	841 37%	0 0%	1 0%
JAN-2016	6 55%	1022 44%	4 36%	462 20%	0 0%	67 3%	1 9%	822 35%	0 0%	1 0%
FEB-2016	7 64%	1064 45%	4 36%	469 20%	0 0%	61 3%	0 0%	813 34%	0 0%	1 0%
MAR-2016	15 79%	1116 46%	2 11%	485 20%	0 0%	60 2%	2 11%	806 33%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2015	2347	34.81	2123	31.49	1137	16.86	179	2.65	74	1.10	882	13.08
FEB-2015	2363	34.79	2110	31.07	1176	17.31	178	2.62	73	1.07	892	13.13
MAR-2015	2398	35.07	2112	30.89	1203	17.60	184	2.69	67	0.98	873	12.77
APR-2015	2391	34.91	2095	30.59	1239	18.09	184	2.69	67	0.98	873	12.75
MAY-2015	2397	34.80	2094	30.40	1277	18.54	179	2.60	68	0.99	873	12.67
JUN-2015	2367	34.29	2078	30.11	1323	19.17	172	2.49	72	1.04	890	12.89
JUL-2015	2372	34.24	2068	29.85	1352	19.52	171	2.47	67	0.97	897	12.95
AUG-2015	2367	34.19	2044	29.52	1382	19.96	168	2.43	70	1.01	893	12.90
SEP-2015	2324	33.56	2032	29.35	1446	20.88	168	2.43	64	0.92	890	12.85
OCT-2015	2326	33.42	2006	28.83	1492	21.44	167	2.40	64	0.92	904	12.99
NOV-2015	2321	33.08	2014	28.71	1543	21.99	160	2.28	67	0.95	911	12.98
DEC-2015	2292	32.76	1984	28.36	1582	22.61	161	2.30	62	0.89	915	13.08
JAN-2016	2291	32.80	1947	27.88	1614	23.11	158	2.26	61	0.87	913	13.07
FEB-2016	2287	32.68	1927	27.54	1669	23.85	153	2.19	59	0.84	903	12.90
MAR-2016	2271	32.42	1907	27.22	1709	24.39	154	2.20	61	0.87	904	12.90

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2015	24	2	2	8	3	9	370
FEB-2015	36	3	3	9	3	16	469
MAR-2015	29	2	5	5	8	7	386
APR-2015	28	8	3	4	3	10	335
MAY-2015	33	4	6	9	5	8	290
JUN-2015	36	6	2	8	8	11	370
JUL-2015	25	6	2	2	6	7	380
AUG-2015	19	2	3	4	2	7	400
SEP-2015	32	7	1	5	2	15	505
OCT-2015	25	5	2	3	4	9	430
NOV-2015	29	5	1	5	6	10	400
DEC-2015	22	2	3	4	5	7	370
JAN-2016	16	2	3	0	5	3	380
FEB-2016	18	4	0	6	3	5	331
MAR-2016	25	4	3	4	7	6	365

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2015	10391	2659
FEB-2015	10437	2666
MAR-2015	10476	2675
APR-2015	10496	2687
MAY-2015	10550	2711
JUN-2015	10636	2758
JUL-2015	10705	2806
AUG-2015	10771	2862
SEP-2015	10856	2917
OCT-2015	10908	2957
NOV-2015	10971	2997
DEC-2015	11017	3024
JAN-2016	11052	3055
FEB-2016	11146	3137
MAR-2016	11213	3189

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved

Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
March 2016

N = 7006

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2016

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2016

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2016

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2016

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	33	45	22
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	69	90	49	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	325	429	249	
THOMPSON/CARIBOO/ SHUSWAP	0-19	5	5	0
	20-34	23	23	18
	35-49	55	64	43
	50+	91	136	76
Total HSDA:	174	228	137	
Total HA:		601	792	457

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	10	10	*
	20-34	53	54	*
	35-49	176	208	*
	50+	362	520	*
Total HA:		601	792	457

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	467	628	361
Female	134	164	96

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	457	53	550	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	17	10
	5 years or more	6	5
	<5 years	10	7
	Total HSDA:	33	22
KOOTENAY BOUNDARY	10 years or more	34	22
	5 years or more	20	16
	<5 years	15	11
	Total HSDA:	69	49
OKANAGAN	10 years or more	169	116
	5 years or more	75	60
	<5 years	81	73
	Total HSDA:	325	249
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	90	63
	5 years or more	34	32
	<5 years	50	42
	Total HSDA:	174	137
Total HA:		601	457

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	310	211
	5 years or more	135	113
	<5 years	156	133
Total HA:		601	457

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	35	50	11	21
KOOTENAY BOUNDARY	63	110	26	41
OKANAGAN	197	672	65	243
THOMPSON/CARIBOO/SHUSWAP	126	411	46	109
Total:	421	1243	148	414

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	0
KOOTENAY BOUNDARY	11
OKANAGAN	45
THOMPSON/CARIBOO/SHUSWAP	38
Total:	94

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	5
	20-34	30	31	23
	35-49	114	124	83
	50+	172	233	143
	Total HSDA:	323	395	254
FRASER NORTH	0-19	18	18	*
	20-34	112	113	*
	35-49	362	411	*
	50+	455	714	*
	Total HSDA:	947	1256	732
FRASER SOUTH	0-19	11	11	7
	20-34	99	101	70
	35-49	356	406	289
	50+	420	625	349
	Total HSDA:	886	1143	715
Total HA:		2156	2794	1701

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	36	36	16
	20-34	241	245	187
	35-49	832	941	632
	50+	1047	1572	866
Total HA:		2156	2794	1701

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1631	2144	1315
Female	525	650	386

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1701	50	610	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	150	112
	5 years or more	92	75
	<5 years	81	67
	Total HSDA:	323	254
FRASER NORTH	10 years or more	453	328
	5 years or more	246	197
	<5 years	248	207
	Total HSDA:	947	732
FRASER SOUTH	10 years or more	408	316
	5 years or more	239	199
	<5 years	239	200
	Total HSDA:	886	715
Total HA:		2156	1701

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1011	756
	5 years or more	577	471
	<5 years	568	474
Total HA:		2156	1701

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries
FRASER Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	126	404	42	81
FRASER NORTH	228	1403	62	268
FRASER SOUTH	201	1174	44	330
Total:	555	2981	148	679

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	180
FRASER NORTH	619
FRASER SOUTH	494
Total:	1293

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	19
	35-49	*	*	67
	50+	*	*	174
	Total HSDA:		305	440
RICHMOND	0-19	5	5	*
	20-34	24	24	*
	35-49	47	50	*
	50+	75	114	*
	Total HSDA:	151	193	118
VANCOUVER	0-19	56	59	7
	20-34	403	411	324
	35-49	1581	1833	1171
	50+	2420	4030	1916
	Total HSDA:	4460	6333	3418
Total HA:		4916	6966	3796

Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
0-19	63	66	8
20-34	447	455	361
35-49	1713	1982	1277
50+	2693	4463	2150
Total HA:	4916	6966	3796

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	4320	6125	3336
Female	594	839	460

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3796	51	610	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	169	140
	5 years or more	53	49
	<5 years	83	71
	Total HSDA:	305	260
RICHMOND	10 years or more	70	51
	5 years or more	38	29
	<5 years	43	38
	Total HSDA:	151	118
VANCOUVER	10 years or more	2268	1636
	5 years or more	1126	870
	<5 years	1066	912
	Never on ART	0	0
	Total HSDA:	4460	3418
Total HA:	4916	3796	

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	2507	1827
5 years or more	1217	948
<5 years	1192	1021
Never on ART	0	0
Total HA:	4916	3796

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	141	367	54	92
RICHMOND	42	260	14	89
VANCOUVER	533	9826	204	5235
Total:	716	10453	272	5416

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	97

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		271	381
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		105	139
SOUTH VANCOUVER ISLAND	0-19	10	10	*
	20-34	45	47	*
	35-49	211	246	*
	50+	384	604	*
	Total HSDA:		650	907
Total HA:		1026	1427	807

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	14	14	5
	20-34	80	85	61
	35-49	327	379	260
	50+	605	949	481
Total HA:		1026	1427	807

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	825	1152	655
Female	201	275	152

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	807	52	470	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	131	103
	5 years or more	66	60
	<5 years	74	58
	Total HSDA:	271	221
NORTH VANCOUVER ISLAND	10 years or more	46	35
	5 years or more	29	23
	<5 years	30	25
	Total HSDA:	105	83
SOUTH VANCOUVER ISLAND	10 years or more	325	228
	5 years or more	168	139
	<5 years	157	136
	Total HSDA:	650	503
Total HA:		1026	807

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	502	366
	5 years or more	263	222
	<5 years	261	219
Total HA:		1026	807

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	170	721	81	182
NORTH VANCOUVER ISLAND	117	234	48	68
SOUTH VANCOUVER ISLAND	182	1528	49	517
Total:	469	2483	178	767

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	46
NORTH VANCOUVER ISLAND	28
SOUTH VANCOUVER ISLAND	88
Total:	162

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		40	48
NORTH WEST	0-19	*	*	0
	20-34	*	*	6
	35-49	*	*	21
	50+	*	*	21
	Total HSDA:		65	96
NORTHERN INTERIOR	0-19	5	5	*
	20-34	25	28	*
	35-49	68	85	*
	50+	73	120	*
	Total HSDA:		171	238
Total HA:		276	382	206

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	7	7	*
	20-34	36	44	*
	35-49	110	141	*
	50+	123	190	*
Total HA:		276	382	206

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	172	241	128
Female	104	141	78

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	206	48	490	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	15	7
	5 years or more	15	9
	<5 years	10	9
	Total HSDA:	40	25
NORTH WEST	10 years or more	17	8
	5 years or more	28	23
	<5 years	20	17
	Total HSDA:	65	48
NORTHERN INTERIOR	10 years or more	52	31
	5 years or more	50	47
	<5 years	69	55
	Total HSDA:	171	133
Total HA:		276	206

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	84	46
	5 years or more	93	79
	<5 years	99	81
Total HA:		276	206

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	32	58	9	10
NORTH WEST	62	141	17	25
NORTHERN INTERIOR	99	389	25	179
Total:	193	588	51	214

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	16
NORTHERN INTERIOR	17
Total:	39

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	*	10	*
	KOOTENAY BOUNDARY	*	6	*
	OKANAGAN	*	29	*
	THOMPSON/CARIBOO/SHUSWAP	*	36	*
	Total HA:	46	81	36
FRASER	FRASER EAST	31	39	24
	FRASER NORTH	63	93	49
	FRASER SOUTH	72	98	57
	Total HA:	166	230	130
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	22	42	18
	RICHMOND	7	12	5
	VANCOUVER	501	782	420
	Total HA:	530	836	443
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	49	74	37
	NORTH VANCOUVER ISLAND	12	21	8
	SOUTH VANCOUVER ISLAND	34	71	26
	Total HA:	95	166	71
NORTHERN	NORTH EAST	9	11	7
	NORTH WEST	32	55	27
	NORTHERN INTERIOR	58	90	54
	Total HA:	99	156	88
Total:		936	1469	768

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	589	943	476
Female	347	526	292

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	768	49	470	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a pill that contains EFAVIRENZ, TENOFOVIR and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Boosted PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Combination Therapy: using at least two drugs simultaneously to more effectively combat a disease. Initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a pill that contains both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead and Janssen trade name for a pill that contains EMTRICITABINE, RILPIVIRINE and TENOFOVIR.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Delavirdine (Rescriptor, DLV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Agouron/ViiV Healthcare.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.





Dolutegravir (DTG): an INTEGRASE INHIBITOR from ViiV Healthcare that has demonstrated activity against HIV in treatment-experienced patients.

Efavirenz (Sustiva, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences that has demonstrated activity against HIV in treatment-experienced patients.

Emtricitabine (FTC): a nucleoside analog from Gilead Sciences. It is currently available as a component of TRUVADA.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

Famciclovir (Famvir): a PRODRUG for an acyclovir-like active compound. It is an approved therapy for shingles and recurrent outbreaks of herpes simplex-2.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer prescribed drugs through the HIV/AIDS Drug Treatment program this current month.

Indinavir (Crixivan, IDV): a PROTEASE INHIBITOR from Merck.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a pill that contains both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (MVC, Celsentri): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.





Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug, such as AZT (ZIDOVUDINE), ddl (DIDANOSINE) or 3TC (LAMIVUDINE), whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds such as TENOFOVIR that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).





PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a pill that contains DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck that has activity against HIV in treatment-experienced patients.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure.

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a pill that contains ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR.

Tenofovir (Viread, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare's trade name for a pill that contains DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare's trade name for a pill that contains ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a pill that contains TENOFOVIR and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

